Targeting LDL cholesterol with LNA

Molecular Therapy Nucleic Acids

Volumn 1, Issue 1, 2012, Pages e6-

  Krieg, Arthur M ^a  

^a Translate Bio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868383682     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2011.8     Document Type: Note

References (6)

1. Lindholm, MW, Elmén, J, Fisker, N, Hansen, HF, Persson, R, Møller, MR et al. (2011). PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates. Mol Ther; e-pub ahead of print 22 November 2011.
2. Horton, JD, Cohen, JC and Hobbs, HH (2007). Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 32: 71-77. (Pubitemid 46199197)
3. Liang, H, Chaparro-Riggers, J, Strop, P, Geng, T, Sutton, JE, Tsai, D et al. (2011). PCSK9 antagonism reduces LDL-cholesterol in statin-treated hypercholesterolemic non-human primates. J Pharmacol Exp Ther; e-pub ahead of print 21 October 2011.
4. Duff, CJ and Hooper, NM (2011). PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets 15: 157-168.
5. Yu, RZ, Lemonidis, KM, Graham, MJ, Matson, JE, Crooke, RM, Tribble, DL et al. (2009). Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 77: 910-919.
6. Swayze, EE, Siwkowski, AM, Wancewicz, EV, Migawa, MT, Wyrzykiewicz, TK, Hung, G et al. (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35: 687-700. (Pubitemid 46232083)